Indaptus Therapeutics, Inc. (INDP): debt financing — Indaptus raises $2.3M via convertible notes and warrants; up to $5M total

Indaptus Therapeutics, Inc.

$2.3M aggregate principal of 6% convertible promissory notes; mature July 28, 2026.
Conversion at 80% of 5-day VWAP, max $0.40; warrants for 200% of conversion shares after approval.
Net proceeds for R&D, Phase 1b/2 trial funding, and general working capital.
Offering may increase to $5M; Paulson Investment Company is exclusive placement agent with 12% fee.
Company must hold special meeting for stockholder approval; note conversion tied to reverse split or 1 year.

item 1.01 item 2.03 item 3.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.98

Indaptus Therapeutics, Inc. incurred convertible notes of aggregate principal amount of $2.3 million with certain accredited investors at 6% per year maturing July 28, 2026.

Instrument: convertible notes
Principal: aggregate principal amount of $2.3 million
Counterparty: certain accredited investors
Rate: 6% per year
Maturity: July 28, 2026
Event: incurrence

Exact text from the filing

the offering in a private placement of convertible promissory notes in the aggregate principal amount of $2.3 million (the "Notes") and warrants (the "Warrants") to purchase shares of common stock, par value $0.01 per share ("Common Stock"). The closing of private placement occurred on June 12, 2025

View on SEC.gov

Browse all debt financings →

Indaptus Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-014972

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.